Oral Contraceptive (OC) Progestin Dose and Breast Proliferation

This study has been completed.

Sponsor:

Collaborator:

Department of Defense

Information provided by:

USC/Norris Comprehensive Cancer Center

ClinicalTrials.gov Identifier:

NCT00972439

First received: September 3, 2009

Last updated: September 4, 2009

Last verified: September 2009

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	November 2008 (Final data collection date for primary outcome measure)

No publications provided by USC/Norris Comprehensive Cancer Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hovanessian-Larsen L, Taylor D, Hawes D, Spicer DV, Press MF, Wu AH, Pike MC, Pearce CL. Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. Contraception. 2012 Sep;86(3):238-43. doi: 10.1016/j.contraception.2011.12.015. Epub 2012 Feb 9.

To Top